Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

LHCOX vs QAAGZX overlap: 47% of top holdings shared

Bottom line

How much do LHCOX and QAAGZX overlap?

47% of their top holdings overlap by weight. 10 securities appear in both funds' top 25, making up 39.8% of LHCOX's assets and 38.6% of QAAGZX's. They share a meaningful core but differ in the rest of the portfolio.

QAAGZX holds far more positions (277 vs 61), so it is broader beyond the top names.

Updated Nov 22, 2026

Overlap at a glance

LHCOXQAAGZX
Weight overlap (top 25)47%
Shared holdings10
Weight in shared holdings39.8%38.6%
Total positions61277
Expense ratio0.68%0.86%
Holdings as ofJul 31, 2026Jun 30, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)

Holdings LHCOX and QAAGZX have in common

Holding% of LHCOX% of QAAGZXOverlap
Eli Lilly & Co10.40%14.06%10.40%
UnitedHealth Group Inc5.39%5.88%5.39%
Johnson & Johnson4.96%6.64%4.96%
Natera Inc3.60%1.44%1.44%
Gilead Sciences Inc3.53%2.79%2.79%
CVS Health Corp3.33%0.93%0.93%
Guardant Health Inc2.61%1.22%1.22%
Thermo Fisher Scientific Inc2.31%2.53%2.31%
Vertex Pharmaceuticals Inc2.24%2.26%2.24%
Protagonist Therapeutics Inc1.44%0.85%0.85%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in LHCOX

  1. Novartis AG — 4.19%
  2. Galderma Group AG — 2.60%
  3. Cogent Biosciences Inc — 2.27%
  4. 10X Genomics Inc — 2.16%
  5. BeOne Medicines Ltd — 2.06%
  6. Ascendis Pharma A/S — 1.99%
  7. AstraZeneca PLC — 1.97%
  8. Madrigal Pharmaceuticals Inc — 1.91%
  9. Bridgebio Pharma Inc — 1.84%
  10. Edwards Lifesciences Corp — 1.78%
  11. Revolution Medicines Inc — 1.67%
  12. Arrowhead Pharmaceuticals Inc — 1.52%
  13. Dianthus Therapeutics Inc — 1.44%
  14. Adaptive Biotechnologies Corp — 1.42%
  15. Illumina Inc — 1.42%

Only in QAAGZX

  1. Abbvie Inc — 5.12%
  2. Merck & Co. Inc. — 4.00%
  3. Bristol-myers Squibb Co — 2.12%
  4. Abbott Laboratories — 1.91%
  5. Intuitive Surgical Inc — 1.89%
  6. Amgen Inc — 1.80%
  7. Stryker Corp — 1.78%
  8. Elevance Health Inc — 1.54%
  9. Danaher Corp — 1.44%
  10. Cardinal Health Inc — 1.04%
  11. Royalty Pharma Plc- Cl A — 0.97%
  12. Tenet Healthcare Corp — 0.94%
  13. Kymera Therapeutics Inc — 0.89%
  14. T. Rowe Price Government Reserve Fund — 0.87%
  15. Moderna Therapeutics Inc — 0.83%

Asset mix

Asset typeLHCOXQAAGZX
Stocks98.2%96.9%
Preferred stock—2.2%
Repurchase agreements1.2%—
Cash & short-term funds0.8%0.9%
Bonds—0.1%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)

Country mix

CountryLHCOXQAAGZX
US78.5%92.3%
CH8.8%0.5%
NL2.2%1.0%
DK2.0%0.7%
GB2.0%1.8%
BE1.4%—
IL1.2%0.2%
JP1.2%0.5%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)

Check another pair

FAQ

How much do LHCOX and QAAGZX overlap?
About 47% by weight. 10 securities appear in both funds' top 25 holdings; they make up 39.8% of LHCOX's assets and 38.6% of QAAGZX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do LHCOX and QAAGZX have in common?
The largest shared holdings are Eli Lilly & Co, UnitedHealth Group Inc, Johnson & Johnson, Gilead Sciences Inc, Thermo Fisher Scientific Inc.
Should I own both LHCOX and QAAGZX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, LHCOX or QAAGZX?
QAAGZX is broader, with 277 positions versus 61 for LHCOX. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.